WO2013170115A1 - Pyridazine and pyridine derivatives as nampt inhibitors - Google Patents

Pyridazine and pyridine derivatives as nampt inhibitors Download PDF

Info

Publication number
WO2013170115A1
WO2013170115A1 PCT/US2013/040481 US2013040481W WO2013170115A1 WO 2013170115 A1 WO2013170115 A1 WO 2013170115A1 US 2013040481 W US2013040481 W US 2013040481W WO 2013170115 A1 WO2013170115 A1 WO 2013170115A1
Authority
WO
WIPO (PCT)
Prior art keywords
carboxamide
phenyl
pyridazin
azetidine
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/040481
Other languages
English (en)
French (fr)
Inventor
Todd M. Hansen
Kenton Longenecker
Howard R. Heyman
Michael L. Curtin
Richard F. Clark
Bryan Sorensen
Zhiqin Ji
George Doherty
Robin Frey
Kevin Woller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Priority to CA2873097A priority Critical patent/CA2873097A1/en
Priority to CN201380036867.6A priority patent/CN104583194A/zh
Priority to EP13726339.8A priority patent/EP2847181A1/en
Priority to MX2014013751A priority patent/MX2014013751A/es
Priority to HK15110586.2A priority patent/HK1209739A1/xx
Priority to JP2015511730A priority patent/JP2015520752A/ja
Publication of WO2013170115A1 publication Critical patent/WO2013170115A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • This invention pertains to compounds which inhibit the activity of NAMPT, compositions containing the compounds, and methods of treating diseases during which NAMPT is expressed.
  • NAD+ (nicotinamide adenine dinucleotide) is a coenzyme that plays a critical role in many physiologically essential processes (Ziegkel, M. Eur. J. Biochem. 267,1550-1564, 2000). NAD is necessary for several signaling pathways including among others poly ADP- ribosylation in DNA repair, mono-ADP-ribosylation in both the immune system and G- protein-coupled signaling, and NAD is also required by sirtuins for their deacetylase activity (Garten, A. et al Trends in Endocrinology and Metabolism, 20, 130-138, 2008).
  • NAMPT also known as pre-B-cell-colony-enhancing factor (PBEF) and visfatin
  • PBEF pre-B-cell-colony-enhancing factor
  • visfatin is an enzyme that catalyzes the phosphoribosylation of nicotinamide and is the rate-limiting enzyme in one of two pathways that salvage NAD.
  • NAMPT inhibitors have potential as anticancer agents. Cancer cells have a higher basal turnover of NAD and also display higher energy requirements compared with normal cells. Additionally, increased NAMPT expression has been reported in colorectal cancer (Van Beijnum, J.R. et al Int. J. Cancer 101, 1 18-127, 2002) and NAMPT is involved in angiogenesis (Kim, S.R. et al. Biochem. Biophys. Res. Commun. 357, 150-156, 2007). Small-molecule inhibitors of NAMPT have been shown to cause depletion of intracellular NAD+ levels and ultimately induce tumor cell death (Hansen, CM et al. Anticancer Res. 20, 421 1 1 -4220, 2000) as well as inhibit tumor growth in xenograft models (Olese, U.H. et al. Mol Cancer Ther. 9, 1609-1617, 2010).
  • NAMPT inhibitors also have potential as therapeutic agents in inflammatory and metabolic disorders (Galli, M. et al Cancer Res. 70, 8- 1 1, 2010).
  • NAMPT is the predominant enzyme in T and B lymphocytes.
  • Selective inhibition of NAMPT leads to NAD+ depletion in lymphocytes blocking the expansion that accompanies autoimmune disease progression whereas cell types expressing the other NAD+ generating pathways might be spared.
  • a small molecule NAMPT inhibitor (FK866) has been shown to selectively block proliferation and induce apoptosis of activated T cells and was efficacious in animal models of arthritis (collagen -induced arthritis) (Busso, N.et al. Plos One 3, e2267, 2008).
  • FK866 ameliorated the manifestations of experimental autoimmune encephalomyelitis (EAE), a model of T-cell mediated autoimmune disorders.
  • EAE experimental autoimmune encephalomyelitis
  • NaMPT activity increases NF-kB transcriptional activity in human vascular endothelial cell, resulting in MMP-2 and MMP-9 activation, suggesting a role for NAMPT inhibitors in the prevention of inflammatory mediated complications of obesity and type 2 diabetes (Adya, R. et. Al. Diabetes Care, 31, 758-760, 2008).
  • X 1 is N and X 2 is CR 1 ;
  • X 1 is CR 1 and X 2 is N;
  • X 1 is CR 1 and X 2 is CR 1 ;
  • Y 1 is C(0)NH, or NHC(O);
  • Z 1 is wherein indicates the point of attachment to Y 1 and x ⁇ indicates the point of attachment to the nitrogen containing heteroaryl;
  • R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, N0 2 , F, CI, Br and I;
  • R 2 is independently selected from the group consisting of CzpCe-alkyl, CzpCe-alkenyl, CzrC 6 -alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R 2 CzpCe-alkyl, C4-C6- alkenyl, and CzpCe-alkynyl is substituted with one or more substituents independently selected from the group consisting of R 3 , OR 3 , SR 3 , S(0)R 3 , S0 2 R 3 , C(0)R 3 , CO(0)R 3 , OC(0)R 3 , OC(0)OR 3 , NH 2 , NHR 3 , N(R 3 ) 2 , NHC(0)R 3 , NR 3 C(0)R 3 , NHS(0) 2 R 3 , NR 3 S(0) 2 R 3 ,
  • NHC(0)OR 3 NR 3 C(0)OR 3 , NHC(0)NH 2 , NHC(0)NHR 3 , NHC(0)N(R 3 ) 2 , NR 3 C(0)NHR 3 , NR 3 C(0)N(R 3 ) 2 , C(0)NH 2 , C(0)NHR 3 , C(0)N(R 3 ) 2 , C(0)NHOH, C(0)NHOR 3 ,
  • each R 2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SR 4 , S(0)R 4 , S0 2 R 4 , C(0)R 4 , OC(0)OR 4 , NH 2 , NHR 4 , N(R 4 ) 2 , NHC(0)R 4 , NR 4 C(0)R 4 , NHS(0) 2 R 4 , NR 4 S(0) 2 R 4 , NHC(0)OR 4 , NR 4 C(0)OR 4 , NHC(0)NH 2 , NHC(0)NHR 4 , NHC(0)N(R 4 ) 2 , NR 4 C(0)NHR 4 , NR 4 C(0)N(
  • R 3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, and heterocyclyl; wherein each R 3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 5 , OR 5 , SR 5 , S(0)R 5 , S0 2 R 5 , C(0)R 5 , CO(0)R 5 , OC(0)R 5 , OC(0)OR 5 , NH 2 , NHR 5 , N(R 5 ) 2 , NHC(0)R 5 , NR 5 C(0)R 5 , NHS(0) 2 R 5 ,
  • R 4 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(0)R 7 , S0 2 R 7 , C(0)R 7 , CO(0)R 7 , OC(0)R 7 , OC(0)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(0)R 7 , NR 7 C(0)R 7 , NHS(0) 2 R 7 ,
  • C(0)NHOR 7 C(0)NHS0 2 R 7 , C(0)NR 7 S0 2 R 7 , S0 2 NH 2 , S0 2 NHR 7 , S0 2 N(R 7 ) 2 , C(0)H, C(0)OH, C(N)NH 2 , C(N)NHR 7 , C(N)N(R 7 ) 2 , CNOH, CNOCH 3 , OH, (O), CN, N 3 , N0 2 , F, CI, Br and I;
  • R 5 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 8 , OR 8 , SR 8 , S(0)R 8 , S0 2 R 8 , NHR 8 , N(R 8 ) 2 , C(0)R 8 , C(0)NH 2 , C(0)NHR 8 , C(0)N(R 8 ) 2 , NHC(0)R 8 , NR 8 C(0)R 8 , NHS0 2 R 8 , NHC(0)OR 8 , S0 2 NH 2 , S0 2 NHR 8 , S0 2 N(R 8 ) 2 , NHC(0)NH 2 , NHC(0)NHR 8 , OH, (O), C(0)OH, N 3 ,
  • R 6 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 9 , OR 9 , SR 9 , S(0)R 9 , S0 2 R 9 , NHR 9 , N(R 9 ) 2 , C(0)R 9 , C(0)NH 2 , C(0)NHR 9 , C(0)N(R 9 ) 2 , NHC(0)R 9 , NR 9 C(0)R 9 , NHS0 2 R 9 , NHC(0)OR 9 ,
  • R 7 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl
  • R 9 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
  • R 10 independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(0)R 10 , S0 2 R 10 , C(0)R 10 , CO(0)R 10 , OC(0)R 10 , OC(0)OR 10 , C(0)C(0)R 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(0)R 10 , NR 10 C(O)R 10 , NHS(0) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(0)OR 10 , NR 10 C(O)OR 10 , NHC(0)NH 2 , NHC(0)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NHR 10 , NR 10 C(O)N(R 10 ) 2 , C(0)NH 2 , C(0)NHR 10 , C(O)N(R 10 ) 2 , C(0)NHOH, C(0)NHOR 10 , C(0)NH
  • R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , S(0)R u , S0 2 R u , C(0)R u , CO(0)R u , OC(0)R u , OC(0)OR u , NH 2 , NHR 11 , N(R U ) 2 , NHC(0)R u , NR u C(0)R u , NHS(0) 2 R u , NR u S(0) 2 R u , NHC(0)OR u , NR u C(0)OR u , NHC(0)NH 2 , NHC(0)NHR u ,
  • R 11 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , OR 13 , C(0)OR 13 , OCF 3 , CF 3 , F, CI, Br and I;
  • R 12 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and R , at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
  • R 2 pyrrolyl is not substituted with two alkyl groups.
  • Z 1 is
  • Z 1 is • - i innrdliircates the point of attachment to Y 1 and %N indicates the point of attachment to the nitrogen containing heteroaryl; and Y 1 is C(0)NH.
  • Z 1 is
  • i innrdliifcate the point of attachment to Y 1 and indicates the point of attachment to the nitrogen containing heteroaryl
  • Y 1 is C(0)NH
  • Z 1 is
  • Y 1 and ⁇ indicates the point of attachment to the nitrogen containing heteroaryl; Y 1 is C(0)NH; X 1 is N and X 2 is CR 1 ; wherein R 2 is phenyl; wherein each R 2 phenyl is substituted with one substituent independently selected from the group consisting of R 4 , OR 4 , and S0 2 R 4 .
  • IC rmula
  • Y 1 is C(0)NH
  • X 1 is N and X 2 is CR 1
  • R 2 is phenyl; wherein each R 2 phenyl is substituted with one substituent independently selected from the group consisting of R , OR , and SO 2 R .
  • Y 1 indicates the point of attachment to Y 1 and indicates the point of attachment to the nitrogen containing heteroaryl
  • Y 1 is C(0)NH
  • X 1 is N and X 2 is CR 1 ;
  • R 2 is phenyl; wherein each R 2 phenyl is substituted with one substituent independently selected from the group consisting of R 4 , OR 4 , and S0 2 R 4 ; and R 1 ,
  • Z 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • i innrdliir cates the point of attachment to Y 1 and indicates the point of attachment to the nitrogen containing heteroaryl
  • Y 1 is C(0)NH
  • X 1 is N and X 2 is CR 1
  • R 2 is phenyl; wherein each R 2 phenyl is substituted with one substituent independently selected from the group consisting of R 4 , OR 4 , and SO 2 R 4 ;
  • R 1 at each occurrence, is hydrogen; and R 4 , at each occurrence, is heterocyclyl.
  • vs- i innrdliir cates the point of attachment to Y 1 and ⁇ indicates the point of attachment to the nitrogen containing heteroaryl
  • Y 1 is C(0)NH
  • X 1 is N and X 2 is CR 1
  • R 2 is phenyl; wherein each R 2 phenyl is substituted with one substituent independently selected from the group consisting of R 4 , OR 4 , and SO 2 R 4 ; and R 1 , at each occurrence, is hydrogen; and R 4 , at each occurrence, is heterocyclyl.
  • Still another embodiment pertains to compounds, which are

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
PCT/US2013/040481 2012-05-11 2013-05-10 Pyridazine and pyridine derivatives as nampt inhibitors Ceased WO2013170115A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2873097A CA2873097A1 (en) 2012-05-11 2013-05-10 Pyridazine and pyridine derivatives as nampt inhibitors
CN201380036867.6A CN104583194A (zh) 2012-05-11 2013-05-10 作为nampt抑制剂的哒嗪和吡啶衍生物
EP13726339.8A EP2847181A1 (en) 2012-05-11 2013-05-10 Pyridazine and pyridine derivatives as nampt inhibitors
MX2014013751A MX2014013751A (es) 2012-05-11 2013-05-10 Piridazina y derivados de piridina como inhibidores de nampt.
HK15110586.2A HK1209739A1 (en) 2012-05-11 2013-05-10 Pyridazine and pyridine derivatives as nampt inhibitors
JP2015511730A JP2015520752A (ja) 2012-05-11 2013-05-10 Ｎａｍｐｔ阻害薬としてのピリダジンおよびピリジン誘導体

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261645692P 2012-05-11 2012-05-11
US61/645,692 2012-05-11
US201261719013P 2012-10-26 2012-10-26
US61/719,013 2012-10-26
US201361779756P 2013-03-13 2013-03-13
US61/779,756 2013-03-13

Publications (1)

Publication Number Publication Date
WO2013170115A1 true WO2013170115A1 (en) 2013-11-14

Family

ID=48539390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/040481 Ceased WO2013170115A1 (en) 2012-05-11 2013-05-10 Pyridazine and pyridine derivatives as nampt inhibitors

Country Status (11)

Country Link
US (4) US8975398B2 (enExample)
EP (1) EP2847181A1 (enExample)
JP (1) JP2015520752A (enExample)
CN (1) CN104583194A (enExample)
AR (1) AR091023A1 (enExample)
CA (1) CA2873097A1 (enExample)
HK (1) HK1209739A1 (enExample)
MX (1) MX2014013751A (enExample)
TW (1) TW201350478A (enExample)
UY (1) UY34804A (enExample)
WO (1) WO2013170115A1 (enExample)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9796712B2 (en) 2014-06-19 2017-10-24 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
WO2018124001A1 (ja) 2016-12-27 2018-07-05 国立研究開発法人理化学研究所 Ｂｍｐシグナル阻害化合物
WO2018177993A1 (de) 2017-03-31 2018-10-04 Bayer Cropscience Aktiengesellschaft Pyrazole zur bekämpfung von arthropoden
US10144742B2 (en) 2014-04-18 2018-12-04 Millennium Pharmaceuticals, Inc. Quinoxaline compounds and uses thereof
US10323018B2 (en) 2015-01-20 2019-06-18 Millennium Pharmaceuticals, Inc. Quinazoline and quinoline compounds and uses thereof
US10710986B2 (en) 2018-02-13 2020-07-14 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2020179859A1 (ja) 2019-03-06 2020-09-10 第一三共株式会社 ピロロピラゾール誘導体
US10774071B2 (en) 2018-07-13 2020-09-15 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11021514B2 (en) 2016-06-01 2021-06-01 Athira Pharma, Inc. Compounds
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11345681B1 (en) 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
US11638762B2 (en) 2016-10-18 2023-05-02 Seagen Inc. Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
US11807626B2 (en) 2020-04-23 2023-11-07 Opna Bio SA Compounds and methods for CD73 modulation and indications therefor
US11931414B2 (en) 2017-04-27 2024-03-19 Seagen Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
US12084431B2 (en) 2018-05-14 2024-09-10 Takeda Pharmaceutical Company Limited Pharmaceutical salts of pyrimidine derivatives and method of treating disorders

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015520752A (ja) * 2012-05-11 2015-07-23 アッヴィ・インコーポレイテッド Ｎａｍｐｔ阻害薬としてのピリダジンおよびピリジン誘導体
CA2942101A1 (en) 2014-03-21 2015-09-24 Abbvie Inc. Anti-egfr antibodies and antibody drug conjugates
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
BR112018075649A2 (pt) 2016-06-08 2019-04-09 Abbvie Inc. anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
EP3468598A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-cd98 antibodies and antibody drug conjugates
EP3468993A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
IL300274A (en) 2016-06-08 2023-04-01 Abbvie Inc Antibodies against B7–H3 and conjugates of drug and antibody
BR112018075645A2 (pt) 2016-06-08 2019-04-09 Abbvie Inc. conjugados de anticorpo fármaco anti-egfr
JP2019521114A (ja) 2016-06-08 2019-07-25 アッヴィ・インコーポレイテッド 抗ｅｇｆｒ抗体薬物コンジュゲート
EP3474667A4 (en) * 2016-06-23 2019-11-27 St. Jude Children's Research Hospital, Inc. SMALL MOLECULAR MODULATORS OF PANTOTHENAT KINASES
CN118562004A (zh) 2016-12-16 2024-08-30 蓝鳍生物医药公司 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法
CA3064697A1 (en) 2017-04-19 2018-10-25 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
CN118994394A (zh) 2017-06-12 2024-11-22 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
US11547709B2 (en) 2017-12-27 2023-01-10 St. Jude Children's Research Hospital, Inc. Methods of treating disorders associated with castor
EP3731844A4 (en) 2017-12-27 2021-08-18 St. Jude Children's Research Hospital, Inc. PANTOTHENATE KINASES SMALL MOLECULE MODULATORS
CA3089754A1 (en) * 2018-01-31 2019-08-08 Bayer Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
WO2020072497A1 (en) * 2018-10-01 2020-04-09 Cornell University Methyl and ethyl nicotinate-riboside-5-phosphates, preparation thereof and methods of use thereof
US20220267271A1 (en) * 2019-07-08 2022-08-25 Mayo Foundation For Medical Education And Research Wnt activators and methods of use
CN114660219A (zh) * 2020-12-23 2022-06-24 安徽古特生物科技有限公司 一种β-烟酰胺单核苷酸的检测方法
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN120958025A (zh) 2022-12-16 2025-11-14 费恩治疗有限公司 针对含cub结构域的蛋白1(cdcp1)的抗体及其用途
CN117285573B (zh) * 2023-09-26 2024-03-26 长沙兴嘉生物工程股份有限公司 一种β-烟酰胺单核苷酸金属络合物及其制备方法

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007271A1 (en) 1993-09-09 1995-03-16 The Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
WO1997010223A1 (en) 1995-09-15 1997-03-20 Pharmacia & Upjohn Company Aminoaryl oxazolidinone n-oxides
WO2003074500A2 (en) * 2002-03-06 2003-09-12 Sanofi-Aventis N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
WO2005016915A1 (en) * 2003-08-14 2005-02-24 Glaxo Group Limited Piperidine/cyclohexane carboxamide derivatives for use as vanilloid receptor modulators
WO2005099353A2 (en) 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
WO2006008754A1 (en) 2004-07-20 2006-01-26 Symed Labs Limited Novel intermediates for linezolid and related compounds
EP1700856A1 (en) * 2003-12-26 2006-09-13 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivative
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US20090093422A1 (en) 2006-10-23 2009-04-09 Roger Tung Oxazolidinone derivatives and methods of use
US7521421B2 (en) 1997-10-08 2009-04-21 Isotechnika Inc. Deuterated cyclosporine analogs and methods of making the same
US20090105147A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105307A1 (en) 2007-02-15 2009-04-23 Guido Galley 2-aminooxazolines as taar1 ligands
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US20090111840A1 (en) 2005-05-31 2009-04-30 Peter Herold Heterocyclic spiro-compounds as aldosterone synthase inhibitors
US7528131B2 (en) 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US7534814B2 (en) 1999-07-30 2009-05-19 Nabriva Therapeutics Ag Mutilin derivatives and their use as antibacterials
US20090131363A1 (en) 2007-10-26 2009-05-21 Harbeson Scott L Deuterated darunavir
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090137457A1 (en) 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
WO2011025799A1 (en) * 2009-08-26 2011-03-03 Glaxo Group Limited Cathepsin c inhibitors
WO2012031199A1 (en) * 2010-09-03 2012-03-08 Forma Therapeutics, Inc. Guanidine compounds and compositions for the inhibition of nampt

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3088016B2 (ja) 1993-03-29 2000-09-18 ゼネカ・リミテッド 血小板凝集抑制剤としての複素環式化合物
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
IL133621A0 (en) 1997-06-26 2001-04-30 Lilly Co Eli Antithrombotic agents
ES2241151T3 (es) 1997-06-26 2005-10-16 Eli Lilly And Company Agentes antitromboticos.
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
CA2416384A1 (en) 2000-07-17 2003-01-16 Takeda Chemical Industries, Ltd. Sulfone derivatives, their production and use
DE60231880D1 (de) 2001-08-07 2009-05-20 Banyu Pharma Co Ltd Spiro isobenzofurane als neuropeptid y rezeptor antagonisten
EP1485348B1 (en) 2002-03-13 2008-06-11 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
EP1348434A1 (en) 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
CA2539117A1 (en) 2003-09-24 2005-04-07 Methylgene Inc. Inhibitors of histone deacetylase
US7244735B2 (en) 2003-12-02 2007-07-17 Vertex Pharmaceuticals Inc. Heterocyclic protein kinase inhibitors and uses thereof
WO2006058338A2 (en) 2004-11-29 2006-06-01 Janssen Pharmaceutica N.V. 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor
JP2008543726A (ja) * 2005-02-24 2008-12-04 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症性疾患の処置のためのｐｇｄ２受容体アンタゴニスト
EP1861396A1 (en) 2005-03-04 2007-12-05 AstraZeneca AB Tricyclic derivatives of azetidine and pyrrole with antibacterial activity
WO2007076055A2 (en) * 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
TW200815426A (en) 2006-06-28 2008-04-01 Astrazeneca Ab New pyridine analogues II 333
WO2008026018A1 (en) 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
PL2079727T3 (pl) 2006-09-15 2016-08-31 Xcovery Inc Inhibitory kinazy
JP2010513458A (ja) * 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用
US20090113874A1 (en) 2007-11-02 2009-05-07 Caterpillar Inc. System and method for electrically regenerating a particulate filter assembly of a generator set
AU2009217982B2 (en) 2008-02-26 2013-04-11 Takeda Pharmaceutical Company Limited Fused heterocyclic derivative and use thereof
EP2098231A1 (en) 2008-03-05 2009-09-09 Topotarget Switzerland SA Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
JP2011527667A (ja) 2008-06-18 2011-11-04 武田薬品工業株式会社 ハロ置換ピリミドジアゼピン
CN102325767B (zh) 2008-12-22 2014-05-14 阵列生物制药公司 7-苯氧基色满羧酸衍生物
JPWO2013146754A1 (ja) * 2012-03-27 2015-12-14 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素５員環誘導体
WO2013144180A1 (en) * 2012-03-28 2013-10-03 Intervet International B.V. Heteroaryl compounds with cyclic bridging unit for use in the treatment helminth infection
US9296723B2 (en) * 2012-05-11 2016-03-29 Abbvie Inc. NAMPT inhibitors
JP2015520752A (ja) * 2012-05-11 2015-07-23 アッヴィ・インコーポレイテッド Ｎａｍｐｔ阻害薬としてのピリダジンおよびピリジン誘導体

Patent Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007271A1 (en) 1993-09-09 1995-03-16 The Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
WO1997010223A1 (en) 1995-09-15 1997-03-20 Pharmacia & Upjohn Company Aminoaryl oxazolidinone n-oxides
US7521421B2 (en) 1997-10-08 2009-04-21 Isotechnika Inc. Deuterated cyclosporine analogs and methods of making the same
US7538189B2 (en) 1997-10-08 2009-05-26 Isotechnika Inc. Methods of making deuterated cyclosporin analogs
US7534814B2 (en) 1999-07-30 2009-05-19 Nabriva Therapeutics Ag Mutilin derivatives and their use as antibacterials
WO2003074500A2 (en) * 2002-03-06 2003-09-12 Sanofi-Aventis N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
WO2005016915A1 (en) * 2003-08-14 2005-02-24 Glaxo Group Limited Piperidine/cyclohexane carboxamide derivatives for use as vanilloid receptor modulators
EP1700856A1 (en) * 2003-12-26 2006-09-13 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivative
WO2005099353A2 (en) 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
WO2006008754A1 (en) 2004-07-20 2006-01-26 Symed Labs Limited Novel intermediates for linezolid and related compounds
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
US20090111840A1 (en) 2005-05-31 2009-04-30 Peter Herold Heterocyclic spiro-compounds as aldosterone synthase inhibitors
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US20090093422A1 (en) 2006-10-23 2009-04-09 Roger Tung Oxazolidinone derivatives and methods of use
US20090105307A1 (en) 2007-02-15 2009-04-23 Guido Galley 2-aminooxazolines as taar1 ligands
US7528131B2 (en) 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090137457A1 (en) 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US20090105147A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090131363A1 (en) 2007-10-26 2009-05-21 Harbeson Scott L Deuterated darunavir
WO2011025799A1 (en) * 2009-08-26 2011-03-03 Glaxo Group Limited Cathepsin c inhibitors
WO2012031199A1 (en) * 2010-09-03 2012-03-08 Forma Therapeutics, Inc. Guanidine compounds and compositions for the inhibition of nampt

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
ADYA, R., DIABETES CARE, vol. 31, 2008, pages 758 - 760
BLAGOJEVIC N ET AL.: "Dosimetry & Treatment Planning for Neutron Capture Therapy", 1994, ADVANCED MEDICAL PUBLISHING, pages: 125 - 134
BLAKE ET AL., J. PHARM. SCI., vol. 64, no. 3, 1975, pages 367 - 391
BRICKNER, S J ET AL., J MED CHEM, vol. 39, no. 3, 1996, pages 673
BRUZZONE, S ET AL., PLOS ONE, vol. 4, 2009, pages E7897
CZAJKA D M; FINKEL A J, ANN. N.Y. ACAD. SCI., vol. 84, 1960, pages 770
CZAKJA D M ET AL., AM. J. PHYSIOL., vol. 201, 1961, pages 357
DIABETES METAB., vol. 23, 1997, pages 251
FOSTER ET AL.: "Advances in Drug Research", vol. 14, 1985, ACADEMIC PRESS, pages: 2 - 36
GALLI, M. ET AL., CANCER RES., vol. 70, 2010, pages 8 - 11
GARTEN, A. ET AL., TRENDS IN ENDOCRINOLOGY AND METABOLISM, vol. 20, 2008, pages 130 - 138
HANSEN, CM ET AL., ANTICANCER RES., vol. 20, 2000, pages 42111 - 4220
KATO ET AL., J. LABELLED COMP. RADIOPHARMACEUT., vol. 36, no. 10, 1995, pages 927 - 932
KIM, S.R. ET AL., BIOCHEM. BIOPHYS. RES. C'OMMUN., vol. 357, 2007, pages 150 - 156
KUSHNER ET AL., CAN. J. PHYSIOL. PHARMACOL., vol. 77, 1999, pages 79 - 88
LIZONDO, J ET AL., DRUGS FUT, vol. 21, no. 11, 1996, pages 1116
MALLCSHAM, B, ORG LETT, vol. 5, no. 7, 2003, pages 963
OLESE, U.H. ET AL., MOL CANCER THER., vol. 9, 2010, pages 1609 - 1617
See also references of EP2847181A1 *
THOMSON J F, ANN. NEW YORK ACAD. SCI, vol. 84, 1960, pages 736
VAN BEIJNUM, J.R. ET AL., INT. J. CANCER, vol. 101, 2002, pages 118 - 127
ZIEGKEL, M., EUR. I BIOCHEM., vol. 267, 2000, pages 1550 - 1564

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10144742B2 (en) 2014-04-18 2018-12-04 Millennium Pharmaceuticals, Inc. Quinoxaline compounds and uses thereof
US9796712B2 (en) 2014-06-19 2017-10-24 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
US10227342B2 (en) 2014-06-19 2019-03-12 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
US11958850B2 (en) 2014-06-19 2024-04-16 Takeda Pharmaceutical Company Limited Heteroaryl compounds for kinase inhibition
US10323018B2 (en) 2015-01-20 2019-06-18 Millennium Pharmaceuticals, Inc. Quinazoline and quinoline compounds and uses thereof
US12421276B2 (en) 2016-06-01 2025-09-23 Athira Pharma, Inc. Methods of treating neurodegenerative disease with substituted n-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide analogues
US11021514B2 (en) 2016-06-01 2021-06-01 Athira Pharma, Inc. Compounds
US11638762B2 (en) 2016-10-18 2023-05-02 Seagen Inc. Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
WO2018124001A1 (ja) 2016-12-27 2018-07-05 国立研究開発法人理化学研究所 Ｂｍｐシグナル阻害化合物
WO2018177993A1 (de) 2017-03-31 2018-10-04 Bayer Cropscience Aktiengesellschaft Pyrazole zur bekämpfung von arthropoden
US11931414B2 (en) 2017-04-27 2024-03-19 Seagen Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
US10710986B2 (en) 2018-02-13 2020-07-14 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11555029B2 (en) 2018-02-13 2023-01-17 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US12338233B2 (en) 2018-02-13 2025-06-24 Gilead Sciences, Inc. PD-1/Pd-L1 inhibitors
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US12084431B2 (en) 2018-05-14 2024-09-10 Takeda Pharmaceutical Company Limited Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
US12269812B2 (en) 2018-07-13 2025-04-08 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10774071B2 (en) 2018-07-13 2020-09-15 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2020179859A1 (ja) 2019-03-06 2020-09-10 第一三共株式会社 ピロロピラゾール誘導体
US11807626B2 (en) 2020-04-23 2023-11-07 Opna Bio SA Compounds and methods for CD73 modulation and indications therefor
US12202818B2 (en) 2020-04-23 2025-01-21 Opna Bio SA Compounds and methods for CD73 modulation and indications therefor
US11345681B1 (en) 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
US12331039B2 (en) 2020-06-05 2025-06-17 Khora Spv 1, Llc Inhibitors of fibroblast growth factor receptor kinases

Also Published As

Publication number Publication date
CA2873097A1 (en) 2013-11-14
MX2014013751A (es) 2015-08-07
HK1209739A1 (en) 2016-04-08
US20130303510A1 (en) 2013-11-14
UY34804A (es) 2013-12-31
EP2847181A1 (en) 2015-03-18
CN104583194A (zh) 2015-04-29
US8975398B2 (en) 2015-03-10
US20130303509A1 (en) 2013-11-14
US20150141398A1 (en) 2015-05-21
AR091023A1 (es) 2014-12-30
US20170065575A1 (en) 2017-03-09
JP2015520752A (ja) 2015-07-23
TW201350478A (zh) 2013-12-16

Similar Documents

Publication Publication Date Title
US8975398B2 (en) NAMPT inhibitors
US10093624B2 (en) NAMPT and ROCK inhibitors
US9193723B2 (en) NAMPT inhibitors
WO2013170113A1 (en) Nampt inhibitors
US9796708B2 (en) Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors
WO2014139328A1 (en) Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
US9758511B2 (en) NAMPT inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13726339

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2873097

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2015511730

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/013751

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2013726339

Country of ref document: EP